134 related articles for article (PubMed ID: 29771413)
1. Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.
Cai DW; Chen D; Sun SP; Liu ZJ; Liu F; Xian SZ; Wu PS; Kong GQ
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2572-2579. PubMed ID: 29771413
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
4. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Zhang M; Mukherjee N; Bermudez RS; Latham DE; Delaney MA; Zietman AL; Shipley WU; Chakravarti A
Prostate; 2005 Aug; 64(3):293-302. PubMed ID: 15754318
[TBL] [Abstract][Full Text] [Related]
6. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PER3 Inhibits Self-Renewal Capability and Chemoresistance of Colorectal Cancer Stem-Like Cells via Inhibition of Notch and β-Catenin Signaling.
Zhang F; Sun H; Zhang S; Yang X; Zhang G; Su T
Oncol Res; 2017 May; 25(5):709-719. PubMed ID: 27983919
[TBL] [Abstract][Full Text] [Related]
8. Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway.
Deng G; Ju X; Meng Q; Yu ZJ; Ma LB
Mol Med Rep; 2015 Sep; 12(3):4427-4433. PubMed ID: 26081222
[TBL] [Abstract][Full Text] [Related]
9. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
10. Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling.
Sha J; Li J; Wang W; Pan L; Cheng J; Li L; Zhao H; Lin W
Biomed Pharmacother; 2016 Dec; 84():177-184. PubMed ID: 27657825
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Samli H; Samli M; Vatansever B; Ardicli S; Aztopal N; Dincel D; Sahin A; Balci F
World J Urol; 2019 Jun; 37(6):1117-1126. PubMed ID: 30244336
[TBL] [Abstract][Full Text] [Related]
12. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
14. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
[TBL] [Abstract][Full Text] [Related]
15. GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.
Liu C; Wang W; Lin P; Xie H; Jiang S; Jia H; Li R; Wang N; Yu X
Biochem Biophys Res Commun; 2021 Jul; 562():119-126. PubMed ID: 34051575
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.
Castilla C; Flores ML; Medina R; Pérez-Valderrama B; Romero F; Tortolero M; Japón MA; Sáez C
Mol Cancer Ther; 2014 Oct; 13(10):2372-83. PubMed ID: 25122070
[TBL] [Abstract][Full Text] [Related]
17. DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer.
Zhao HF; Zhang ZC; Shi BK; Jiang XZ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6849-6857. PubMed ID: 31486484
[TBL] [Abstract][Full Text] [Related]
18. The role of the SHH gene in prostate cancer cell resistance to paclitaxel.
Statkiewicz M; Maryan N; Lipiec A; Grecka E; Grygorowicz MA; Omiotek M; Gorska A; Mikula M; Malecki M
Prostate; 2014 Aug; 74(11):1142-52. PubMed ID: 24925370
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
Lanzi C; Cassinelli G; Cuccuru G; Supino R; Zuco V; Ferlini C; Scambia G; Zunino F
Prostate; 2001 Sep; 48(4):254-64. PubMed ID: 11536305
[TBL] [Abstract][Full Text] [Related]
20. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Chen L; Cao H; Feng Y
World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
